Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Chunyan Luan & Baoan Chen. (2019) Clinical application of obinutuzumab for treating chronic lymphocytic leukemia. Drug Design, Development and Therapy 13, pages 2899-2909.
Read now
Read now
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan & Ofer Mandelboim. (2018) Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). OncoImmunology 7:6.
Read now
Read now
Luciano Levato & Stefano Molica. (2018) Rituximab in the management of acute lymphoblastic leukemia. Expert Opinion on Biological Therapy 18:2, pages 221-226.
Read now
Read now
Othman Al-Sawaf, Kirsten Fischer, Anja Engelke, Natali Pflug, Michael Hallek & Valentin Goede. (2017) Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. Drug Design, Development and Therapy 11, pages 295-304.
Read now
Read now
Barbara Ma & Chaitra Ujjani. (2017) The clinical development of obinutuzumab for the treatment of follicular lymphoma. Cancer Management and Research 9, pages 103-113.
Read now
Read now
Lakshminarayanan Nandagopal & Amitkumar Mehta. (2017) Treatment approaches of hard-to-treat non-Hodgkin lymphomas. Expert Review of Hematology 10:3, pages 259-273.
Read now
Read now
G. Reda, N. Orofino, R. Cassin, M. Sciumè, B. Fattizzo & A. Cortelezzi. (2016) Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations. Expert Opinion on Drug Safety 15:6, pages 865-873.
Read now
Read now
Lukáš Smolej. (2015) Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmacogenomics and Personalized Medicine 8, pages 1-7.
Read now
Read now
Sonia Cerquozzi & Carolyn Owen. (2015) Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 13-22.
Read now
Read now
Karen Seiter & Aleksandra Mamorska-Dyga. (2015) Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clinical Interventions in Aging 10, pages 951-961.
Read now
Read now
Tim Illidge, Eleanor J Cheadle, Claire Donaghy & Jamie Honeychurch. (2014) Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opinion on Biological Therapy 14:10, pages 1507-1517.
Read now
Read now
Saskia Meyer, Jeanette HW Leusen & Peter Boross. (2014) Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer. mAbs 6:5, pages 1133-1144.
Read now
Read now
Articles from other publishers (37)
Michele Clerico, Simone Ragaini & Federica Cavallo. 2024. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal
103
122
.
Kenny Misael Calvillo-Rodríguez, Helen Yarimet Lorenzo-Anota, Cristina Rodríguez-Padilla, Ana Carolina Martínez-Torres & Daniel Scott-Algara. (2023) Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. Frontiers in Immunology 14.
Crossref
Crossref
Namita Varudkar, Elisabeth M. Shiffer, Jeremiah L. Oyer, Alicja Copik & Griffith D. Parks. (2023) Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells. PLOS ONE 18:5, pages e0285532.
Crossref
Crossref
Yoshika IwataHitoshi Katada, Momoko Okuda, Yoshiaki DoiTim Jang Ching, Asako HaradaAkira TakeiriMasaki HondaMasayuki Mishima. (2023) Preclinical <i>in vitro</i> evaluation of immune suppression induced by GYM329, Fc-engineered sweeping antibody. The Journal of Toxicological Sciences 48:7, pages 399-409.
Crossref
Crossref
Talha Munir, Jake Emmerson, Anna Hockaday, Jamie B. Oughton, Dena Howard, David Phillips, Jeff Neilson, Nicholas Pemberton, Shankara Paneesha, Ben Kennedy, Andy Rawstron & Peter Hillmen. (2022)
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the
UK National Cancer Research Institute
phase
II
/
III GALACTIC
trial
. British Journal of Haematology 199:5, pages 707-719.
Crossref
Crossref
Zhaoming Wang & George J Weiner. (2021) Immune checkpoint markers and anti-CD20-mediated NK cell activation. Journal of Leukocyte Biology 110:4, pages 723-733.
Crossref
Crossref
Mélanie Gauthier, Caroline Laroye, Danièle Bensoussan, Cédric Boura & Véronique Decot. (2021) Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. Critical Reviews in Oncology/Hematology 160, pages 103261.
Crossref
Crossref
Marina Martinić Kavur, Gordan Lauc & Marija Pezer. 2021. Comprehensive Glycoscience. Comprehensive Glycoscience
439
478
.
Farheen Mir, Federico Mattiello, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, Christopher R. Bolen, Andrea Knapp, Tina Nielsen & Carla Casulo. (2020)
Follicular Lymphoma Evaluation Index (
FLEX
): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure after frontline immunochemotherapy
. American Journal of Hematology 95:12, pages 1503-1510.
Crossref
Crossref
Shanshan Luo, Moran Wang, Huafang Wang, Desheng Hu, Peter F. Zipfel & Yu Hu. (2020) How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application. Frontiers in Immunology 11.
Crossref
Crossref
Josée Golay & Ronald P. Taylor. (2020) The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies 9:4, pages 58.
Crossref
Crossref
W Heo, N Jin, M S Park, H-Y Kim, S M Yoon, J Lee & J Y Kim. (2020) STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane. Clinical and Experimental Immunology 200:3, pages 260-271.
Crossref
Crossref
Behnaz Valipour, Ali Abedelahi, Elahe Naderali, Kobra Velaei, Aliakbar Movassaghpour, Mehdi Talebi, Soheila Montazersaheb, Mohammad Karimipour, Masoud Darabi, Hadi Chavoshi & Hojjatollah Nozad Charoudeh. (2020) Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. Life Sciences 242, pages 117223.
Crossref
Crossref
Pallawi Torka, Mathew Barth, Robert Ferdman & Francisco J. Hernandez-Ilizaliturri. (2019) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. Current Hematologic Malignancy Reports 14:5, pages 426-438.
Crossref
Crossref
Luisa Bell, Tobias Koeniger, Sabine Tacke & Stefanie Kuerten. (2019) Characterization of blood–brain barrier integrity in a B-cell-dependent mouse model of multiple sclerosis. Histochemistry and Cell Biology 151:6, pages 489-499.
Crossref
Crossref
Matthew J. Barth & Stanton C. Goldman. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas
27
55
.
Franck Morschhauser, Gilles SallesSteven Le GouillHerve TillyCatherine ThieblemontKrimo BouabdallahBettina FabianiCédric MénardKarin Tarte, Guillaume Cartron & Roch Houot. (2018) An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood 132:14, pages 1486-1494.
Crossref
Crossref
Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, Anne Papaioannou, Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Bruno Daubeuf, Laura Cons, Lucile Broyer, Matilde D'Asaro, Thomas Matthes, Simon LeGallou, Thierry Fest, Karin Tarte, Robert K. Clarke Hinojosa, Eulàlia Genescà Ferrer, José María Ribera, Aditi Dey, Katharine Bailey, Adele K. Fielding, Linda Eissenberg, Julie Ritchey, Michael Rettig, John F. DiPersio, Marie H. Kosco-Vilbois, Krzysztof Masternak, Nicolas Fischer, Limin Shang & Walter G. Ferlin. (2018) Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. Molecular Cancer Therapeutics 17:8, pages 1739-1751.
Crossref
Crossref
Fabien Pitoiset, Lydie Cassard, Karim El Soufi, Lisa Boselli, Jonathan Grivel, Alexandra Roux, David Klatzmann, Nathalie Chaput & Michelle Rosenzwajg. (2018) Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry Part A 93:8, pages 793-802.
Crossref
Crossref
Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle‐Rowson & Pablo Umaña. 2018. Successful Drug Discovery. Successful Drug Discovery
245
289
.
Florian Cymer, Hermann Beck, Adelheid Rohde & Dietmar Reusch. (2018) Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential. Biologicals 52, pages 1-11.
Crossref
Crossref
Guillaume CartronHervé Watier. (2017) Obinutuzumab: what is there to learn from clinical trials?. Blood 130:5, pages 581-589.
Crossref
Crossref
Venkat Reddy, Christian Klein, David A. Isenberg, Martin J. Glennie, Geraldine Cambridge, Mark S. Cragg & Maria J. Leandro. (2017) Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 56:7, pages 1227-1237.
Crossref
Crossref
E J Cheadle, G Lipowska-Bhalla, S J Dovedi, E Fagnano, C Klein, J Honeychurch & T M Illidge. (2016) A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia 31:7, pages 1611-1621.
Crossref
Crossref
Sophia N. Karagiannis, Debra H. Josephs, Heather J. Bax & James F. Spicer. (2017) Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer. Cancer Research 77:11, pages 2779-2783.
Crossref
Crossref
Laura M. Rogers, Sarah L. Mott, Brian J. Smith, Brian K. Link, Deniz Sahin & George J. Weiner. (2017) Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. Clinical Cancer Research 23:4, pages 954-961.
Crossref
Crossref
Kensei Tobinai, Christian Klein, Naoko Oya & Günter Fingerle-Rowson. (2016) A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Advances in Therapy 34:2, pages 324-356.
Crossref
Crossref
Ronald P. Taylor & Margaret A. Lindorfer. (2016) Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. Seminars in Immunology 28:3, pages 309-316.
Crossref
Crossref
Carin I. M. Dahlberg, Dhifaf Sarhan, Michael Chrobok, Adil D. Duru & Evren Alici. (2015) Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Frontiers in Immunology 6.
Crossref
Crossref
Tim Illidge, Christian Klein, Laurie H. Sehn, Andrew Davies, Gilles Salles & Guillaume Cartron. (2015) Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews 41:9, pages 784-792.
Crossref
Crossref
Katelyn T. Byrne, Robert H. Vonderheide, Elizabeth M. Jaffee & Todd D. Armstrong. (2015) Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. Cancer Immunology Research 3:6, pages 590-597.
Crossref
Crossref
Valentin Goede, Christian Klein & Stephan Stilgenbauer. (2015) Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody. Oncology Research and Treatment 38:4, pages 185-192.
Crossref
Crossref
Caroline S Breton, Aimable Nahimana, Dominique Aubry, Julie Macoin, Pierre Moretti, Martin Bertschinger, Samuel Hou, Michel A Duchosal & Jonathan Back. (2014) A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Christian Klein, Marina Bacac, Pablo Umaña & Michael Wenger. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1695
1732
.
Josée GolayFabio Da RoitLuca BolognaClaudia Ferrara, Jeanette H. Leusen, Alessandro RambaldiChristian Klein & Martino Introna. (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:20, pages 3482-3491.
Crossref
Crossref
Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umana, Gerhard Niederfellner, Marina Bacac & Christian Klein. (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab
In Vitro
and in Xenograft Models
. Molecular Cancer Therapeutics 12:10, pages 2031-2042.
Crossref
Crossref
Franz Buchegger, Steven M. Larson, Jean-Pierre Mach, Yves Chalandon, Pierre-Yves Dietrich, Anne Cairoli, John O. Prior, Pedro Romero & Daniel E. Speiser. (2013) Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology 2013, pages 1-8.
Crossref
Crossref